0A43 Stock Overview A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Inovio Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Inovio Pharmaceuticals Historical stock prices Current Share Price US$1.90 52 Week High US$14.60 52 Week Low US$1.76 Beta 0.84 1 Month Change -52.62% 3 Month Change -66.59% 1 Year Change -78.48% 3 Year Change -96.57% 5 Year Change n/a Change since IPO -98.84%
Recent News & Updates Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $30 million. Dec 14
New minor risk - Market cap size Dec 13 Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.
INOVIO Announces New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial Dec 03
New major risk - Financial position Nov 15
Third quarter 2024 earnings released: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023) Nov 15 See more updates Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $30 million. Dec 14
New minor risk - Market cap size Dec 13 Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.
INOVIO Announces New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial Dec 03
New major risk - Financial position Nov 15
Third quarter 2024 earnings released: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023) Nov 15
Inovio Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 06
New major risk - Share price stability Sep 04 Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $60 million. Aug 13
New minor risk - Profitability Aug 11
Second quarter 2024 earnings released: US$1.19 loss per share (vs US$1.61 loss in 2Q 2023) Aug 09
Inovio Pharmaceuticals, Inc. Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 Jul 26
Inovio Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 25
INOVIO Announces INO-3107 Receives the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway Jul 12
INOVIO Appointsof Steven Egge as Chief Commercial Officer Jul 03
New minor risk - Profitability May 14
First quarter 2024 earnings released: US$1.31 loss per share (vs US$1.89 loss in 1Q 2023) May 14
Inovio Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 13, 2024 May 01 Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $35.937522 million. Apr 16
Inovio Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024 Apr 12
New minor risk - Profitability Mar 08
Forecast to breakeven in 2026 Mar 08
Full year 2023 earnings released: US$6.09 loss per share (vs US$14.07 loss in FY 2022) Mar 07
Inovio Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 06, 2024 Feb 22
New minor risk - Profitability Feb 07
Forecast to breakeven in 2026 Feb 07
New minor risk - Profitability Nov 13
Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.15 loss in 3Q 2022) Nov 10
Inovio Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 27
Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107 Oct 11
New minor risk - Market cap size Oct 05
Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.46 loss in 2Q 2022) Aug 10
Inovio Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Jul 28 Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 2000 Value Index
First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.36 loss in 1Q 2022) May 11
INOVIO Presents New Data from A Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis May 09 Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023
Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023 Feb 16
Inovio Reports Positive Phase 1B Results for INO-4201 as an Ebola Booster for rVSV-Zebov (Ervebo®) Feb 03
Inovio Pharmaceuticals, Inc. Announces Strategic Reorganization and 11% Reduction of Full-Time Employees Feb 01
Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.29 loss in 3Q 2021) Nov 10
INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800 Oct 28
Inovio Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Oct 14
Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.39 loss in 2Q 2021) Aug 11
Inovio Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo(R) (cemiplimab) in Patients with Newly Diagnosed GBM May 28 INOVIO Announces Board Changes
First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.27 loss in 1Q 2021) May 11
No longer forecast to breakeven Apr 27
No longer forecast to breakeven Mar 03
Inovio Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 16
High number of new directors Dec 31
INOVIO Updates on Phase 3 Program for VGX-3100 for HPV-Associated Cervical High-Grade Squamous Intraepithelial Lesions Dec 15
No longer forecast to breakeven Nov 24
Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.12 profit in 3Q 2020) Nov 10
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico Sep 24
Forecast to breakeven in 2023 Sep 23
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its Covid-19 DNA Vaccine Candidate, INO-4800 Aug 27
Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.83 loss in 2Q 2020) Aug 10
INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate Aug 10
INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine against Middle East Respiratory Syndrome, a Coronavirus Disease Aug 05 Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 3000 Growth Index
Forecast breakeven pushed back to 2024 May 15
Inovio's Pan-Covid-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies May 13
First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.26 loss in 1Q 2020) May 12
INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine May 11
INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel Mar 16
INOVIO Announces Positive Results from REVEAL 1, Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-Based HPV Immunotherapy for the Treatment of High-Grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18 Mar 03
Full year 2020 earnings released: US$1.07 loss per share (vs US$1.21 loss in FY 2019) Mar 02
Revenue beats expectations Mar 02
QIAGEN N.V. and Inovio Pharmaceuticals Announces an Extension of Their Partnership with A New Master Collaboration Agreement to Develop Liquid Biopsy-Based Companion Diagnostic Cervical Dysplasia Feb 25
INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa Feb 24
Inovio Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 01, 2021 Feb 17
New 90-day high: US$13.34 Jan 28
Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150.45 million. Jan 22
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy in Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18 Jan 08
INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China Jan 05
INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine Dec 25
New 90-day low: US$9.87 Dec 23
Inovio Pharmaceuticals, Inc. Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19 Dec 09
INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP) Nov 25 Shareholder Returns 0A43 GB Biotechs GB Market 7D 1.1% 2.7% 0.8% 1Y -78.5% -24.0% 4.4%
See full shareholder returns
Return vs Industry: 0A43 underperformed the UK Biotechs industry which returned -24% over the past year.
Return vs Market: 0A43 underperformed the UK Market which returned 4.4% over the past year.
Price Volatility Is 0A43's price volatile compared to industry and market? 0A43 volatility 0A43 Average Weekly Movement 13.2% Biotechs Industry Average Movement 9.1% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.5%
Stable Share Price: 0A43's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A43's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.
Show more Inovio Pharmaceuticals, Inc. Fundamentals Summary How do Inovio Pharmaceuticals's earnings and revenue compare to its market cap? 0A43 fundamental statistics Market cap US$51.16m Earnings (TTM ) -US$112.88m Revenue (TTM ) US$203.41k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0A43 income statement (TTM ) Revenue US$203.41k Cost of Revenue US$81.97m Gross Profit -US$81.77m Other Expenses US$31.11m Earnings -US$112.88m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.32 Gross Margin -40,198.50% Net Profit Margin -55,491.09% Debt/Equity Ratio 0%
How did 0A43 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/04 07:15 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Inovio Pharmaceuticals, Inc. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Aydin Huseynov Benchmark Company Geoffrey Meacham BofA Global Research Jonathan Aschoff Brean Capital
Show 17 more analysts 
